Ildiko Hammond is exhausted. Not only is caring for her severely disabled daughter a full-time job, it is also financially draining. But yesterday, the Lismore mother of two received some welcome news. Mrs Hammond and about 19,000 other carers of children with profound disabilities will soon qualify for a $550-a-fortnight...
Latest News
A couple have made a heartfelt appeal for help to get their terminally ill son to America for treatment. Adel and Damien Elliott from Enniskillen were left shattered by the news that both their sons Marc (4) and two-month-old Matthew have the incurable and deadly illness adrenoleukodystrophy, a rare genetic...
Durham, NC – Karen Kump of Elko, Nevada, knew the lump on her right breast should be checked by a doctor when she first noticed it in July 2022. “But my granddaughter was getting married, and I wanted the attention to be on her,” she said. Kump, 78, didn’t know...
The grandparents of a four-year-old Enniskillen boy diagnosed with a rare terminal illness are appealing for public support to help them raise money towards his dietary needs, treatment, hospital trips, and even a possible cure. Marc Elliott is the son of Damien and Adel and brother to six-week-old Matthew. They...
COPENHAGEN, Denmark and BOSTON – Hemab ApS (“Hemab”), a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders, today announces the successful closing of a US$ 55M Series A financing. The investment was led by Novo Holdings, HealthCap and RA Capital Management. Benny Sorensen, MD, PhD, who served on Hemab’s Board...
COPENHAGEN, Denmark and CAMBRIDGE, Mass. — Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today presented initial results from Phase 1 of its ongoing evaluation of HMB-001. A novel bispecific antibody, HMB-001 is in development as a prophylactic treatment for the...
CAMBRIDGE, Mass. and COPENHAGEN, Denmark — Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced positive results from its completed Phase 2 multiple ascending dose (MAD) portion of the CL-101 study of sutacimig for the prophylactic treatment of Glanzmann thrombasthenia...
OSLO, Norway — Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for GLIX1, a first-in-class small molecule targeting DNA repair vulnerabilities in glioblastoma and other solid tumors....
OSLO, Norway — Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for GLIX1 for the treatment of malignant glioma, a category of devastating brain cancers that includes glioblastoma. Significant clinical benefit beyond current therapies. The...
OSLO, Norway — Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending Orphan Drug Designation (ODD) for GLIX1, the company’s lead molecule, for the treatment of glioma, one...